These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11292186)

  • 21. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab effectiveness in a patient with juvenile systemic lupus erythematosus complicated with acquired Von Willebrand syndrome.
    Jimenez AR; Vallejo ES; Cruz MZ; Cruz AC; Miramontes JV; Jara BS
    Lupus; 2013 Dec; 22(14):1514-7. PubMed ID: 23989733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.
    Castaman G; Tosetto A; Rodeghiero F
    Am J Hematol; 1992 Oct; 41(2):132-6. PubMed ID: 1415174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.
    Viallard JF; Pellegrin JL; Vergnes C; Borel-Derlon A; Clofent-Sanchez G; Nurden AT; Leng B; Nurden P
    Br J Haematol; 1999 May; 105(2):532-7. PubMed ID: 10233433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of autoimmune severe acquired von Willebrand syndrome (type 3-like).
    Gavva C; Patel P; Shen YM; Frenkel E; Sarode R
    Transfus Apher Sci; 2017 Jun; 56(3):431-433. PubMed ID: 28512017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acquired von Willebrand syndrome in a patient with immune thrombocytopenic purpura].
    Ihara A; Suzuki N; Matsushita T; Ichinose A
    Rinsho Ketsueki; 2015 Jul; 56(7):901-4. PubMed ID: 26256928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acquired von Willebrand syndrome].
    de Lange DW; Fijnheer R; Wittebol S
    Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
    Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
    Federici AB; Mannucci PM
    Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.